

ITW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/815,995 Confirmation No.: 7292  
Applicant : Edward M. SELLERS et al.  
Filed : April 2, 2004  
Title : THERAPEUTIC AND DIAGNOSTIC METHODS DEPENDENT  
ON CYP2A ENZYMES  
TC/Art Unit : 1614  
Examiner: : Unassigned  
  
Docket No. : 62805.000041  
Customer No. : 21967

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

The subject application is a Divisional of U.S. Application No. 09/584,669 (Attorney Docket No. 62805.000020), filed June 1, 2000. In accordance with 37 C.F.R. § 1.98(d), patent documents and published articles which were cited in the prior application are listed on the accompanying Form PTO-SB/08A, but copies of these documents are not enclosed as they were provided in the prior application. However, copies will be forwarded at the request of the Examiner.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action and within three months of the


filing date of the application. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: July 2, 2004

By:

  
Jeffrey T. Perez  
Registration No. 52,110

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

JTP/sdw



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number 10/815,995

Filing Date April 2, 2004

First Named Inventor Edward M. SELLERS et al.

Art Unit 1614

Examiner Name Unassigned

Sheet 1 of 2

Attorney Docket Number 62805.000041

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 5653987	08-05-1997	Modi et al.	
	2.	US 5760049	06-02-1998	Viner	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	3.	WO	95/34679	12/21/1995	Jeffrey et al.		<input type="checkbox"/>	<input type="checkbox"/>

**NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	4.	NAKAJIMA, M. et al., "Characterization of CYP2A6 involved in 3'-hydroxylation of continine in human liver microsomes," J. Pharmacol. Exp. Therap., (1996) Vol. 277, No. 2, pp. 1010-1015		
	5.	NAKAJIMA, M. et al., "Role of human cytochrome P4502A6 in C-oxidation of nicotine," Drug Metabol. Dispos., (1996) Vol. 24, No. 11, pp. 1212-1217		
	6.	TSUJIMOTO, A. et al., "Potent inhibitory action of pilocarpine on hepatic drug metabolism," Jpn. J. Pharmacol., (1972) Vol. 22, No. 5, 736		
	7.	TSUJIMOTO, A. et al., "A study of the nature of pilocarpine on hepatic drug-metabolizing enzymes," Biochem. Pharmacol., (1977) Vol. 26, No. 21, pp. 2072-2074		
	8.	FOTH, H. et al., "Nicotine metabolism is isolated perfused lung and liver of phenobarbital-and benzoflavone-treated rats," Arch. Toxicol., (1991) Vol. 65, No. 1, pp. 68-72		

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number 10/815,995

Filing Date April 2, 2004

First Named Inventor Edward M. SELLERS et al.

Art Unit 1614

Examiner Name Unassigned

Attorney Docket Number 62805.000041

Sheet 2 of 2

## NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	9.	KYEREMATEN, G. A. et al., "Metabolism of nicotine by hepatocytes," Biochem. Pharmacol., (1990) Vol. 40, No. 8, pp. 1747-1756		
	10.	YAMAZAKI, H. et al., "Cytochrome P450 sE1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes," Carcinogenesis (1992) Vol. 13, No. 10, pp. 1789-1794		
	11.	CAPLUS, DN 120:238085, Garnitskij et al., SU 1803032 A1, 1993/03/23, English abstract with notes from oral translation		
	12.	MAYS et al., Methoxsalen is a potent inhibitor of caffeine in humans, Clin. Pharmacol. Ther., 42:621-626 (1987)		
	13.	MAENPAA et al., "Metabolic interactions of methoxsalen and coumarin in humans and mice," Biochem. Pharmacol., 48(7), (1994), 1363-9		
	14.	BENOWITZ, N. L. et al., "Deficient C-Oxidation of nicotine," Clinical Pharmacol. And Therap., 57(5):590-594 (1995) (Abstract)		
	15.	Copy of International Search Report of PCT/CA98/01093, August 1999		

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.